skip to Main Content

NantKwest, NantCell to Test NANT Vaccine in Phase 1/2 Trial for Pancreatic Cancer Patients

Newsfeed image, light gray text on dark gray background
The U.S. Food and Drug Administration (FDA) has granted investigational new drug status to the NANT cancer vaccine, to be assessed in a Phase 1/2 clinical trial (NCT03136406) for pancreatic cancer patients who progressed during or following standard-of care therapy.

The vaccine, developed by NantCell and NantKwest, is the first combination immunotherapy protocol that orchestrates the delivery of metronomic low-dose radiation and chemotherapy with molecularly informed tumor-associated antigen vaccines and off-the-shelf “natural killer” (NK) cells. Read more . . .

Back To Top